Condition: Hepatocellular Carcinoma · Sponsor: Robert C. Martin
The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
This description comes directly from the study's public registry record.
Robert Martin, MD, PhD · 502-629-3355 · robert.martin@louisville.edu
Always discuss trial participation with your own doctor first.
| University of Louisville | Louisville, Kentucky, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526338